Evidence map›Paper›PMID 41844845›Full record

ArticleScientific reports2026

The epidemiology of neurocognitive disorders in Hungary.

Christopher Váraljai, András Attila Horváth, Anita Kamondi

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Christopher VáraljaiDepartment of Neurosurgery and Neurointervention, Semmelweis University, Laky Adolf utca 44, Budapest, 1145, Hungary. christophervaraljai@gmail.com.
András Attila HorváthNeurocognitive Research Centre, Nyírő Gyula National Institute of Psychiatry and Addictology, Lehel utca 59, Budapest, 1135, Hungary.
Anita KamondiDepartment of Neurosurgery and Neurointervention, Semmelweis University, Laky Adolf utca 44, Budapest, 1145, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a lack of data on the epidemiological characteristics of NCD (neurocognitive. disorder) in Hungary. We aimed to assess the prevalence and incidence of NCD in Hungary, by sex and age groups, and to determine the proportion of diagnostic procedures performed on patients, the prevalence of comorbidities within this population, and the medication used to treat these patients. Descriptive statistical analysis based on data from the National Health Insurance Fund and the Central Statistical Office. Data are for the years 2016 to 2021. The prevalence of NCD in people over 65 in 2016 was 6.64%, decreasing to 5.58% in 2021. The annual incidence in 2016 was 65,505, which decreased to 42,668 in 2021. 40% of incident. patients received a CT scan of the skull. Around 80% of patients were diagnosed with hypertension. 75% had cerebrovascular disease in 2016, which decreased to 59.3% in 2021. A third of patients were diagnosed with type 2 diabetes. In 2016, 8.99% of patients filled their prescriptions for NCD, this figure did not change significantly by 2021. The prevalence of NCD in Hungary decreased significantly after 2019, presumably due to the decreased use of healthcare facilities during the COVID-19 pandemic.

Indexed as

Neurocognitive DisordersAdolescentAdultAgedAged, 80 and overComorbidityCOVID-19Diabetes Mellitus, Type 2FemaleHumansHungaryHypertensionIncidenceMaleMiddle AgedPrevalenceComorbidityDementiaEpidemiologyHungaryNeurocognitive disorderPrevalence

Identifiers

PMID41844845
PMCPMC13133360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.